Navigation Links
Many Phase 3 Cancer Drug Trials Yield Effective Medicines
Date:3/24/2008

Between a third and a half of these studies bring real clinical improvements, researchers say

MONDAY, March 24 (HealthDay News) -- From 25 percent to 50 percent of new cancer treatments tested in phase 3 randomized clinical trials are eventually found to be effective, say American researchers who analyzed data from 624 phase 3 trials involving more than 216,000 patients.

The trials were all conducted by U.S. National Cancer Institute-funded cooperative groups since 1955.

Dr. Benjamin Djulbegovic, of the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida in Tampa, and colleagues found that 30 percent of the trials had statistically significant results.

In 80 percent of those trials, new treatments were found to be superior to established treatments. The risk-benefit ratio favored new treatments in 41 percent of comparisons, and favored standard treatments in 59 percent of comparisons.

"The real effects of new treatments compared with standard treatments in terms of patient outcomes such as survival is best measured by quantitative pooling of data," the study authors wrote. "When done this way, new treatments are, on average, found to be slightly superior to standard treatments, with a five percent relative reduction in the death rate. This, of course, should not be understood as the average effects of new discoveries being equally spread among all patients."

The researchers also found that breakthrough therapies were discovered in 15 percent of the trials and, in two percent of cases, the breakthroughs reduced the death rate by more than 50 percent.

The study was published in the March 24 issue of the journal Archives of Internal Medicine. Two of the study co-authors received consulting fees and grant support from drug makers Sanofi-Aventis, AMGEN, and Eli Lilly and Company.

"In conclusion, society has received a good return on its investment in the cooperative oncology group system," which funds the trials, the study authors wrote. "The public can expect that about 25 percent to 50 percent of new cancer treatments that reach the stage of assessment in clinical trials will prove to be successful. This pattern of successes has become more consistent over time. However, our results also indicate that the absolute number of discoveries might be improved if the proportion of inconclusive trials is reduced."

Cancer is the second leading cause of death in the United States. Over the years, there have been continuous improvements made in survival and other outcomes, in large part due to the introduction of new treatments tested in clinical trials, according to background information in the study.

More information

The U.S. National Cancer Institute has more about cancer clinical trials.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, March 24, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Cancer treatments in phase 3 trials successful up to half of the time
2. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
3. MGH initiates phase I diabetes trial
4. Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
5. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
6. Akela Pharma initiates its first abuse deterrent opioid Phase I clinical trial
7. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
8. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
9. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
10. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
11. Positive results from phase 1 clinical trials of cuprindro
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Many Phase 3 Cancer Drug Trials Yield Effective Medicines
(Date:8/24/2017)... (PRWEB) , ... August 24, 2017 , ... ... supplements that help people improve all aspects of their health and wellness, has ... , The step represents a component of Natural Subsistence’s aggressive marketing strategy in ...
(Date:8/24/2017)... ... August 24, 2017 , ... AudioEducator is the country’s top ... coming months, AudioEducator has lined up several training sessions on ICD-10 coding ... experts, these healthcare training conferences are designed to update providers with all the ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... President Business Development and Sector Growth. Mr. Smith joins other recent high-profile hires ... , Mr. Smith’s healthcare career began in 1993, helping physician practices and hospitals ...
(Date:8/23/2017)... ... ... The Stevie® Awards have announced the winners of the Best of the IBA Awards in ... , Nominees in the 2017 IBAs were not able to apply for the Best of ... number of awards won in the IBAs with a Gold Stevie win counting for three ...
(Date:8/23/2017)... , ... August 23, 2017 , ... ... MD , has returned home to Indiana, and is now seeing patients at ... board-eligible ophthalmologist that specializes in the diagnosis and treatment of eye disease, medical ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/4/2017)... , Aug. 4, 2017 The search ... shortly after a physician/patient consult has long been the ... was a notable focus of the largest meeting of ... according to healthcare market research firm Kalorama Information.  The ... testing (POCT) offerings or related supplies and software were ...
(Date:8/3/2017)... Aug. 3, 2017  Opioid addiction and other drugs ... healthcare costs and threatening outcomes, were problems taken on ... IVD industry that support them, met this week. This ... said that drugs of abuse, procalcitonin and acute kidney ... the organization,s 69th meeting in San Diego, ...
Breaking Medicine Technology: